ArticleDiscover oncology2025
A bibliometric analysis of immune response in oral cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC), a type of oral cancer, has a high mortality rate and unfavorable outcomes. Its tumor microenvironment (TME) is intricate and adaptable, with research frequently focusing on the immune reaction. Scholars are exploring ways to enhance survival by bolstering the immune response within the TME. However, a comprehensive trend analysis is lacking. Bibliometric analysis can address this by visualizing research patterns. This study aimed to map these trends in OSCC immunology from 2003 to 2023.
methodsAn immunology-focused search on OSCC was executed within the Web of Science Core Collection, spanning 2003 to 2023. Despite its narrow focus, the search offers a telling glimpse of current researches in this domain. Bibliometric analysis was performed using VOSviewer, Citespace, Scimago Graphica, and R software.
resultsFrom 2003 to 2023, the field has published 805 publications, predominantly from China and the United States. The most valuable contributing author is Friedman Jay, topping co-citation counts. The journal Oral Oncology is the leading journal with the highest publication volume. An analysis of keyword bursts indicated that research into nivolumab and chemotherapy is a prevalent area of interest within the clinical community. These findings suggest that neoadjuvant immunotherapy represents a promising avenue for future therapeutic development.
conclusionsThis study presented a summary of the current trends and research frontiers in the field of immunological aspects of OSCC. This summary can serve as a valuable reference and a source of new insights into this area of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.